Endocrine Abstracts

Introduction: Diabetic nephropathy (DN) is a severe complication of type 1 diabetes mellitus (T1DM) and has become common primary disease leading to end-stage renal disease worldwide. Abnormalities in lipid metabolism is very important in the progression of renal damage in patients with T1DM.

Aim: to assess the relationship between lipid abnormalities and diabetic nephropathy in type 1 diabetes mellitus patients.

Methods: we performed a retrospective analysis of clinical data from Litdiane database from 2013 to 2016. 18-67-year-old 100 patients with type 1 diabetes were enrolled in the study. Participants filled questionnaires about T1DM, disease duration, complications and treatment. Anthropometric parameters height and weight were measured. Laboratory tests including total cholesterol, triglycerides, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, glycated hemoglobin (HbA_1c), creatinine, albumin in 24h urine sample were performed. Study included group 1 of 50 T1DM patients with DN and group 2 of 50 T1DM patients without DN. Patients taking statins and patients with eGFR <30 ml/min were excluded from the trial.

Results: 62 females and 38 males participated in the study. Mean age in DN group was 38.4±11.2 years and in group without DN 30.4±10.3 years. Mean duration of diabetes was 17.7±11.1 years, average body mass index (BMI) was 24.2±3.9 kg/m², HbA1c 9 ± 2.2 %, eGFR 92±30.9 ml/min/1.73m². Patients with macroalbuminuria (26%) and microalbuminuria (40%) had significantly increased serum cholesterol (P<0.05). LDL cholesterol was significantly higher (3.3±0.9) in DN group (P=0.005). Cases of hypertriglyceridemia were significantly more frequent between males than females (39.5% vs 9.7% P<0.001). Statistically significant relationship was verified between higher serum cholesterol (5.8±1.5) and DN group (P=0.001).

Conclusion: lipid metabolism is significantly impaired among patients with diabetic nephropathy. Early monitoring, regular screening and appropriate lipid-lowering drug therapy may delay further renal complications in type 1 diabetes mellitus patients.